These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 32861287)

  • 21. Emerging therapies in mantle cell lymphoma.
    Hanel W; Epperla N
    J Hematol Oncol; 2020 Jun; 13(1):79. PubMed ID: 32552760
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel Treatments for Mantle Cell Lymphoma: From Targeted Therapies to CAR T Cells.
    Wallace D; Reagan PM
    Drugs; 2021 Apr; 81(6):669-684. PubMed ID: 33783717
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Understanding resistance mechanisms to BTK and BCL2 inhibitors in mantle cell lymphoma: implications for design of clinical trials.
    Agarwal R; Dawson MA; Dreyling M; Tam CS
    Leuk Lymphoma; 2018 Dec; 59(12):2769-2781. PubMed ID: 29912596
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR-2 retrospective chart review study.
    Hess G; Dreyling M; Oberic L; Gine E; Zinzani PL; Linton K; Vilmar A; Jerkeman M; Chen JMH; Ohler A; Stilgenbauer S; Thieblemont C; Lambert J; Zilioli VR; Sancho JM; Jiménez-Ubieto A; Fischer L; Eyre TA; Keeping S; Park JE; Wu JJ; Siddiqi R; Reitan J; Wade S; Salles G
    Br J Haematol; 2023 Aug; 202(4):749-759. PubMed ID: 36257914
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Primary Central Nervous System Lymphoma: Evolving Biologic Insights and Recent Therapeutic Advances.
    Chihara D; Dunleavy K
    Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):73-79. PubMed ID: 33288483
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Post-BTK inhibitor mantle cell lymphoma: When is CAR-T not the answer?
    McCulloch R
    Br J Haematol; 2023 Aug; 202(4):718-719. PubMed ID: 37188352
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Are novel agents ready to assume the mantle in the frontline treatment of mantle cell lymphoma?
    Yamshon S; Martin P
    Clin Adv Hematol Oncol; 2021 Jun; 19(6):376-382. PubMed ID: 34106911
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Bruton tyrosine kinase inhibitor CC-292 shows activity in mantle cell lymphoma and synergizes with lenalidomide and NIK inhibitors depending on nuclear factor-κB mutational status.
    Vidal-Crespo A; Rodriguez V; Matas-Cespedes A; Lee E; Rivas-Delgado A; Giné E; Navarro A; Beà S; Campo E; López-Guillermo A; Lopez-Guerra M; Roué G; Colomer D; Pérez-Galán P
    Haematologica; 2017 Nov; 102(11):e447-e451. PubMed ID: 28838994
    [No Abstract]   [Full Text] [Related]  

  • 29. Bruton tyrosine kinase inhibitors preserve anti-CD19 chimeric antigen receptor T-cell functionality and reprogram tumor micro-environment in B-cell lymphoma.
    Luo W; Li C; Wu J; Tang L; Wang X; Zhang Y; Wu Z; Huang Z; Xu J; Kang Y; Xiong W; Deng J; Hu Y; Mei H
    Cytotherapy; 2023 Jul; 25(7):739-749. PubMed ID: 37074239
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mantle cell lymphoma: insights into therapeutic targets at the preclinical level.
    Klener P
    Expert Opin Ther Targets; 2020 Oct; 24(10):1029-1045. PubMed ID: 32842810
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of Bruton's tyrosine kinase inhibitors in the management of mantle cell lymphoma.
    Hanna KS; Campbell M; Husak A; Sturm S
    J Oncol Pharm Pract; 2020 Jul; 26(5):1190-1199. PubMed ID: 32279595
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pleiotropic Action of Novel Bruton's Tyrosine Kinase Inhibitor BGB-3111 in Mantle Cell Lymphoma.
    Li CJ; Jiang C; Liu Y; Bell T; Ma W; Ye Y; Huang S; Guo H; Zhang H; Wang L; Wang J; Nomie K; Zhang L; Wang M
    Mol Cancer Ther; 2019 Feb; 18(2):267-277. PubMed ID: 30413649
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiac side effects of bruton tyrosine kinase (BTK) inhibitors.
    Tang CPS; McMullen J; Tam C
    Leuk Lymphoma; 2018 Jul; 59(7):1554-1564. PubMed ID: 28901789
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In brief: Acalabrutinib (Calquence) for mantle cell lymphoma.
    Med Lett Drugs Ther; 2018 Nov; 60(1559):e184. PubMed ID: 30681658
    [No Abstract]   [Full Text] [Related]  

  • 35. Clinicopathological characteristics, outcomes and pattern of mutations in patients with follicular lymphoma who progressed on Bruton tyrosine kinase inhibitors.
    Jain P; Kanagal-Shamanna R; San Lucas FA; Nastoupil L; Romaguera J; Fayad L; Oki Y; Westin JR; Medeiros LJ; Wang M; Fowler N
    Br J Haematol; 2018 Sep; 182(5):718-723. PubMed ID: 28771675
    [No Abstract]   [Full Text] [Related]  

  • 36. Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside.
    Wu J; Zhang M; Liu D
    Oncotarget; 2017 Jan; 8(4):7201-7207. PubMed ID: 27776353
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Harnessing the Effects of BTKi on T Cells for Effective Immunotherapy against CLL.
    Mhibik M; Wiestner A; Sun C
    Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31861854
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acalabrutinib for adults with mantle cell lymphoma.
    Jurczak W; Długosz-Danecka M; Wang M
    Expert Rev Clin Pharmacol; 2019 Mar; 12(3):179-187. PubMed ID: 30638402
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ibrutinib in the management of Waldenstrom macroglobulinemia.
    Yosef A; Touloukian EZ; Nambudiri VE
    J Oncol Pharm Pract; 2019 Mar; 25(2):434-441. PubMed ID: 29996737
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting protein kinase C in mantle cell lymphoma.
    Rauert-Wunderlich H; Rudelius M; Ott G; Rosenwald A
    Br J Haematol; 2016 May; 173(3):394-403. PubMed ID: 26914495
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.